DekaBank Deutsche Girozentrale’s Aratana Therapeutics, Inc. PETX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-17,600	Closed	-$102K	–	1120
2015 Q4	$102K	Hold	17,600	–	–	﹤0.01%	964
2015 Q3	$149K	Buy	17,600 +700	+4%	+$11.8K	﹤0.01%	922
2015 Q2	$255K	Buy	16,900 +600	+4%	+$8.66K	﹤0.01%	830
2015 Q1	$264K	Buy	+16,300	New	+$290K	﹤0.01%	842

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

DekaBank Deutsche Girozentrale's PETX Position: Q1 2016 in Review

DekaBank Deutsche Girozentrale sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2016, closing a stake of 17,600 shares — an estimated $102K sold.

DekaBank Deutsche Girozentrale first reported a position in PETX in Q1 2015 and held it in 4 quarters. The position peaked at $264K in Q1 2015. 95 funds tracked by Wall St. Rank hold PETX as of Q1 2016.

DekaBank Deutsche Girozentrale reported no remaining Aratana Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 17,600 Aratana Therapeutics, Inc. shares in Q1 2016, an estimated $102K.
DekaBank Deutsche Girozentrale first reported a position in Aratana Therapeutics, Inc. in Q1 2015 and held it in 4 quarters.
DekaBank Deutsche Girozentrale's Aratana Therapeutics, Inc. position peaked at $264K in Q1 2015.
95 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2016.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2016, filed 13 May 2016.